Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations

Bio-Techne ( NASDAQ:TECH ) Full Year 2024 Results Key Financial Results Revenue: US$1.16b (up 2.0% from FY 2023). ... Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations. editorial-team ...

0%
OFF

Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations

2 weeks from now

Bio-Techne ( NASDAQ:TECH ) Full Year 2024 Results Key Financial Results Revenue: US$1.16b (up 2.0% from FY 2023). ... Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations. editorial-team ...

yahoo.com

$1.07
OFF

Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations

2 weeks from now

Aug 9, 2024 · EPS: US$1.07 (down from US$1.81 in FY 2023). NasdaqGS:TECH Earnings and Revenue Growth August 9th 2024. All figures shown in the chart above are for the trailing 12 …

simplywall.st

0%
OFF

Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations

2 weeks from now

Aug 9, 2024 · Bio-Techne ( NASDAQ:TECH ) Full Year 2024 Results Key Financial Results Revenue: US$1.16b (up 2.0% from FY 2023). Net...

sahmcapital.com

2%
OFF

BIO-TECHNE RELEASES FOURTH QUARTER FISCAL 2024 RESULTS :: …

2 weeks from now

Aug 7, 2024 · Full Year Fiscal 2024. Revenue. Net sales for the full year fiscal 2024 increased 2% to $1.2 billion. Organic revenue increased 1%, with acquisitions contributing 1%. Foreign …

bio-techne.com

$0
OFF

Bio-Techne Corporation (NASDAQ:TECH) Q2 2024 Earnings Call …

2 weeks from now

Feb 2, 2024 · Bio-Techne Corporation misses on earnings expectations. Reported EPS is $0.4 EPS, expectations were $0.42. Bio-Techne Corporation isn’t one of the 30 most popular …

insidermonkey.com

33%
OFF

Bio-Techne Corp (TECH) (Q3 2024) Earnings Call Transcript …

2 weeks from now

May 2, 2024 · Operating Margin: Adjusted operating margin 33%, up 290 basis points sequentially, down 400 basis points year-over-year. Segment Performance - Protein Sciences: …

yahoo.com

5%
OFF

Bio-Techne (TECH) Earnings Date And Reports 2025 - MarketBeat

2 weeks from now

Bio-Techne announced Q1 2025 earnings on October 30, 2024, reporting an EPS of $0.42, which beat the consensus estimate of $0.38 by $0.04. Quarterly revenue rose 4.5% year-over-year …

marketbeat.com

$0
OFF

Bio-Techne Corp (TECH) Q4 FY2024 Earnings: GAAP EPS Of $0.

2 weeks from now

Revenue: $306.1 million for the fourth quarter, slightly below the estimated $306.49 million.GAAP EPS: $0.25 per share, a decrease from $0.47 in the same quart ... Bio-Techne Corp (TECH) …

gurufocus.com

$0.48
OFF

Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call …

2 weeks from now

May 2, 2024 · Bio-Techne Corporation (NASDAQ:TECH) Q3 2024 Earnings Call Transcript May 1, 2024 Bio-Techne Corporation beats earnings expectations. Reported EPS is $0.48, …

yahoo.com

$0.38
OFF

A Look Ahead: Bio-Techne's Earnings Forecast - Nasdaq

2 weeks from now

Oct 29, 2024 · Analysts anticipate Bio-Techne to report an earnings per share (EPS) of $0.38. Investors in Bio-Techne are eagerly awaiting the company's announcement, hoping for news …

nasdaq.com

14%
OFF

BlackRock Full Year 2024 Earnings: EPS Misses Expectations

2 weeks from now

8 hours ago · BlackRock ( NYSE:BLK ) Full Year 2024 Results Key Financial Results Revenue: US$20.4b (up 14% from FY 2023). ... BlackRock Full Year 2024 Earnings: EPS Misses …

yahoo.com

FAQs about Bio-Techne Full Year 2024 Earnings: EPS Misses Expectations Coupon?

Who is the CEO of Bio-Techne?

You may begin. David Clair: Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, Bio-Techne's Chief Executive Officer; Chuck Kummeth, Bio-Techne's former Chief Executive Officer and current Senior Advisor to the company, and Jim Hippel, Chief Financial Office. ...

Is Bio-Techne Corporation a good stock to buy?

Bio-Techne Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the Bio-Techne […] ...

What does Bio-Techne do?

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. ...